80 results about "Myocardial cell" patented technology

The application provides an active exosome stent coating, a vascular stent and a preparation method and application, and belongs to the technical field of biomedical intervention instruments. The active exosome stent coating of the application adopts stem cell-derived myocardial cell active exosomes which are strengthened by active components of traditional Chinese medicine. Compared with commercial myocardial cells, the stem cell-derived myocardial cells have more significant effects of promoting blood vessels and tissue repair and regeneration, and stronger cytokine secretion capacity. The preparation method of the active exosome stent coating of the application adjusts the introduction sequence and premixing mode of active components such as exosomes and drugs, and enhances the homogeneity and stability. The vascular stent prepared by using the active exosome stent coating of the application has reasonable sequential release kinetics design, can realize precise targeted regulation on human coronary artery smooth muscle cells (HCASMC) in vitro, does not affect the repair potential of endothelial cells, and solves the contradiction between traditional stents in terms of "anti-proliferation and promotion of healing".

This invention discloses a cardioprotective compound composition and its preparation based on improving the absorption rate of coenzyme Q10, relating to the fields of pharmaceuticals and functional foods. The core active ingredients of this composition consist of coenzyme Q10, vitamin E, and black pepper extract, with a specific mass ratio range for each. It can also be combined with pharmaceutically acceptable carriers and antioxidant synergists to prepare various oral formulations. This invention, through the construction of a ternary active component with a specific ratio, achieves in vivo synergistic effects on absorption promotion and antioxidant regeneration, solving the technical problems of low oral bioavailability and insufficient accumulation of myocardial-targeted activity in existing coenzyme Q10 preparations. It significantly improves the conversion efficiency of coenzyme Q10 into a usable active form for cardiomyocytes and can be widely applied in the preparation of drugs and functional foods for the prevention or treatment of heart diseases.

The application discloses application of a BLM helicase inhibitor in treating myocardial hypertrophy. The application firstly finds that the BLM helicase inhibitor ML216 can significantly inhibit cardiac hypertrophy and myocardial cell fibrosis, thereby providing a new drug for treating myocardial cell hypertrophy diseases in the field, and providing practical experimental evidence and scientific basis for treating myocardial cell hypertrophy diseases, and having a good application prospect in treating myocardial hypertrophy and / or cardiac hypertrophy.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

This invention discloses the application of alismazone B acetate in the preparation of drugs for the prevention or treatment of hypertrophic cardiomyopathy and its related symptoms. This invention is the first to propose the use of alismazone B acetate (AB23a) for the prevention or treatment of hypertrophic cardiomyopathy. The invention utilizes AB23a to directly treat cardiomyocytes obtained from directed differentiation of human embryonic stem cells in vitro, finding that AB23a treatment significantly inhibits the hypertrophic phenotype of human embryonic stem cell-cardiomyocytes. Feeding mice with hereditary hypertrophic cardiomyopathy caused by gene mutations to a diet containing AB23a showed that AB23a significantly alleviated pathological myocardial hypertrophy and improved cardiac function in mice. AB23a can be used to prepare drugs against hereditary hypertrophic cardiomyopathy, providing a new approach and method for treating hypertrophic cardiomyopathy. AB23a is the most important medicinal component of the traditional Chinese medicine Alisma plantago-aquatica, is safe for organisms, and has good clinical application prospects.

The application belongs to the technical field of biological medicine, and discloses application of targeted inhibition of TRIM47 in preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury. By establishing a mouse myocardial ischemia-reperfusion injury model, it is found that, compared with a model group, specific knockout of the TRIM47 gene in the heart can significantly improve the heart function of a myocardial ischemia-reperfusion injury mouse, reduce the infarct area after myocardial reperfusion, and also reduce the hypertrophy of myocardial cells and matrix deposition of the mouse, and improve myocardial remodeling. Based on the above findings, TRIM47 can be used as an action target of a myocardial ischemia-reperfusion injury treatment drug, and an inhibitor thereof can be used for preparing a drug for preventing or treating myocardial ischemia-reperfusion injury.

The application discloses application of a lipoic acid analogue in preparation of a product for relieving myocardial cell hypertrophy, and the lipoic acid analogue DMAE-LA is N -(2-(dimethylamino)ethyl)-5-(1,2-dithiopentyl-3-yl)valeric amide. DMAE-LA can effectively reduce ISO-induced myocardial hypertrophy of mice, reduce heart weight index and ANP and BNP expression, and significantly improve heart function. A small dose (2-10 μM) of a lysosome-targeting lipoic acid analogue DMAE-LA can effectively improve Ang II-induced myocardial hypertrophy and oxidative stress in H9c2 cells, and the protective effect is better than that of a high dose (200-400 μM) of LA. As a new substitute of traditional LA, DMAE-LA shows great potential for prevention and treatment of cardiovascular diseases.

The application discloses application of a genetic lineage tracing mouse model in regulation of myocardial cell transformation into osteoblasts, and belongs to the technical field of biotechnology.The tracing mouse model is induced to have myocardial calcification through high-dose steroids or myocardial infarction operation, the tracing mouse model expresses a label protein in myocardial cells of mammals, and the label protein expression in the myocardial cells is realized through a Cre / loxP system.The genetic lineage tracing mouse model provided by the application can be used for detecting myocardial cell transformation into osteoblasts, and can also be used for developing or screening drugs capable of preventing myocardial calcification or preparing products for developing or screening the drugs capable of preventing myocardial calcification.

This invention discloses the application of 12S-HHT in the preparation of drugs for the prevention and / or treatment of cardiovascular diseases. The study found that after administration, 12S-HHT acts as a signaling molecule in vivo, activating the PPARδ signaling pathway and regulating the expression of a series of downstream genes related to energy metabolism and mitochondrial function, thereby achieving a therapeutic effect. Mechanism of action: By binding to and activating PPARδ, it upregulates its downstream target genes. ANGPTL1 It promotes fatty acid oxidation and enhances the "metabolic flexibility" of myocardial cells.

This invention discloses the application of lipoic acid analog formulations in the preparation of anti-cardiomyocyte senescence products. The lipoic acid analog DMAE-LA is N-(2-(dimethylamino)ethyl)-5-(1,2-dithiopentane-3-yl)pentanamide, with a concentration of 2-25 μM. DMAE-LA pretreatment effectively reduces intracellular ROS, improves mitochondrial function, inhibits the overexpression of p21 and HMGB1, and restores Lamin B1 levels, thereby alleviating the senescent manifestations of cardiomyocytes. DMAE-LA reduces H₂S oxidative depletion by inhibiting ROS generation and may promote H₂S synthase activity, increasing endogenous H₂S levels and further enhancing cellular antioxidant capacity. In summary, DMAE-LA can significantly inhibit cardiomyocyte senescence through multiple antioxidant mechanisms and organelle function protection, providing a potential intervention strategy for targeting cellular senescence in cardiovascular diseases.

The application relates to the technical field of electrophysiological detection, in particular to a sensor for synchronous acquisition of myocardial cell signals, a device and a related method, the sensor comprising a first control module, a second control module and a sensing module; a signal input end of the first control module is connected with a signal output end of the sensing module, a signal output end of the first control module is connected with a signal input end of the second control module, and a signal output end of the second control module is connected with an upper computer; the sensing module comprises a microelectrode array and an interdigital electrode array arranged on a glass substrate, the microelectrode array and the interdigital electrode array are electrically connected with the signal output end, the microelectrode array is used for sensing an electrophysiological signal, the interdigital electrode array is used for sensing an impedance signal, the first control module is used for applying an excitation signal to the sensor and collecting a response signal, and the second control module is used for processing the response signal output by the first control module. The application can realize synchronous acquisition of multiple parameter signals of cells.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

This invention belongs to the field of biomedical technology, specifically involving Trmt61a The application of genes in the preparation of drugs for treating pathological myocardial hypertrophy. This invention provides... Trmt61a The application of genes in the preparation of drugs for treating pathological myocardial hypertrophy, the aforementioned Trmt61a The nucleotide sequence of the gene is shown in SEQ ID NO.1. Animal experiments have shown that knocking down... Trmt61a Gene knockdown can significantly improve cardiac contractile function after aortic arch coarctation surgery, alleviate cardiomyocyte hypertrophy, reduce the degree of cardiac fibrosis, and effectively treat pathological myocardial hypertrophy. This invention is the first to demonstrate knockdown... Trmt61a Genes can effectively improve pathological myocardial hypertrophy, providing a new drug development path and target for the prevention and treatment of this disease, and have important medicinal value and clinical application prospects.

The application discloses a kind of short peptides simulating RhoE C end, derivative and its pharmaceutical use in treating ventricular remodeling, belong to biological medicine technical field.The short peptide and derivative contain RhoE C end 200-240 linear function domain, can be combined and activated WWP2, remove HGS self-inhibition, start endosome-lysosome degradation pathway.Short peptide sequence is as SEQ ID NO.1, derivative can be coupled with TAT, T7 or RVG membrane penetrating peptide (SEQ ID NO.2-4), and endocytosed to myocardial cell by caveolin high efficiency delivery.The application solves the defects that existing anti-ventricular remodeling drug inhibits protective autophagy flow, and the ability of eliminating toxic protein is limited, can efficiently eliminate damaged mitochondria and misfolded protein, inhibits myocardial hypertrophy, fibrosis, improves cardiac remodeling, provides safe and effective treatment strategy for related diseases.

The present invention discloses a heart-protective complex composition for improving the absorption rate of Coenzyme Q10 and a preparation method thereof, relating to the technical field of medicine and functional foods. The core active ingredients comprise Coenzyme Q10, Vitamin E, and black pepper extract within a specific mass ratio range. Pharmaceutically acceptable carriers and antioxidant synergists may also be combined to prepare various oral dosage forms. By constructing a ternary active component system with a specific ratio, the present invention achieves temporal synergy between absorption promotion and antioxidant regeneration in vivo, thereby solving the technical problems of low oral bioavailability and insufficient myocardial targeted accumulation of existing Coenzyme Q10 preparations. It significantly enhances the conversion efficiency of Coenzyme Q10 into the active form available to myocardial cells, and can be widely used in the preparation of drugs or functional foods for preventing or treating heart diseases.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

The application discloses a ginseng and astragalus root-danshen total phenolic acid heart function improving composition, and relates to the technical field of medicines.The active ingredients of the composition are composed of three chemical monomers of ginsenoside Rg1, astragaloside B and danshensu, and the weight ratio is 1:0.5 to 1:2 to 3.Through combination of the three specific monomers in the accurate proportion, multiple key nodes of myocardial cell energy metabolism can be synergistically regulated, and myocardial energy metabolism disorder under heart failure state can be systematically intervened.The composition has clear components, controllable quality, and can be prepared into various dosage forms such as tablets and capsules.Compared with medicinal material extracts with complex components, the composition provided by the application has the advantages of clear action mechanism, accurate proportion, stable quality and the like, and provides a new drug selection for the treatment of heart failure.

The application belongs to the technical field of biological medicine, and particularly relates to application of a GCN2 kinase inhibitor in preparation of a drug for treating heart failure with preserved ejection fraction. 18 H 12 ClF2N5O3S, the inhibitor can inhibit the activity of GCN2 kinase, and exhibits significant therapeutic effect in a disease model: can obviously improve ventricular diastolic function (E / E' ratio is reduced), reduce the level of heart failure markers, reduce cardiomyocyte hypertrophy and interstitial fibrosis, inhibit the expression of oxidative stress level and inflammatory factors, reduce the accumulation of triglyceride and total cholesterol in myocardium and serum, and improve obesity-related insulin resistance and metabolic disorder. The application provides a novel targeted treatment strategy and candidate drug for heart failure with preserved ejection fraction.

The invention discloses a myocardial cell systolic function analysis method, system and device and a medium. The method comprises the following steps: setting an import generation parameter based on a myocardial cell rhythmic systolic video sequence, splitting and reading frame by frame based on the myocardial cell rhythmic systolic video sequence, and converting to generate a grayscale image; calculating two adjacent frames of pixel point displacement vector fields based on the gray level image, acquiring flow field components in different directions based on the pixel point displacement vector fields, and converting to generate a time speed sequence curve; smoothing and filtering the processed signal based on a time-speed sequence curve, detecting and identifying a key time phase of a contraction period based on the time-speed sequence curve, and completing period judgment and inspection; and calculating contraction process kinetic parameters based on the period. According to the method, a one-key operation process of video import, pixel size setting, parameter calculation and result export is realized through a software interface, unmarked, high-throughput and automatic myocardial cell systolic function evaluation is realized, and technical support is provided for drug screening and disease model function research.

The application relates to application of siRNA-OTUB1 in preparation of drugs for preventing or treating myocardial cell hypertrophy, and belongs to the biomedical technical field.The nucleotide sequence of the OTUB1 gene is shown as SEQ ID NO.1, and the targeted nucleotide sequence of the siRNA-OTUB1 for specifically interfering with the expression of the OTUB1 gene is shown as SEQ ID NO.2 or SEQ ID NO.3.The application innovatively proposes a strategy for preventing or treating myocardial cell hypertrophy by taking deubiquitinase OTUB1 as a core target point and by interfering with the expression thereof.In a myocardial cell experiment of a milk rat, the application of the designed siRNA-OTUB1 can effectively reduce the expression levels of OTUB1 mRNA and OTUB1 protein, and further reduce the degree of myocardial cell hypertrophy.Based on the finding, the OTUB1 gene can be developed as a novel treatment target point for myocardial cell hypertrophy, is used for designing a targeted drug, and provides a new technical thought for precise treatment of myocardial hypertrophy.

This invention discloses the application of MITF inhibitors in the preparation of drugs for the prevention and / or treatment of sorafenib cardiotoxicity, belonging to the field of biomedical technology. This invention is the first to discover that the transcription factor MITF is a core regulatory factor of sorafenib cardiotoxicity. Sorafenib can specifically upregulate the expression and transcriptional activity of MITF in cardiomyocytes, and its expression level is positively correlated with the degree of cardiomyocyte damage. By inhibiting the expression or activity of MITF, sorafenib-induced cardiomyocyte hypertrophy and damage can be significantly reversed. This invention provides a novel specific intervention target for the prevention and treatment of sorafenib cardiotoxicity, and has significant scientific and clinical translational value.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The application belongs to the technical field of biotechnology, and particularly relates to a culture medium for preparing a 3D heart organoid and a preparation method of the 3D heart organoid. The components in the culture medium provided by the application have a synergistic effect, the CM-1 culture medium enables 3D cell balls to form a primitive germ layer structure in the culture medium, the CM-2 culture medium promotes differentiation of myocardial precursor cells into functional myocardial cells, the CM-3 culture medium helps to form a contraction structure of mature myocardial cells and supports functional maturation, and the CM-4 culture medium improves cell viability in the process of induction and differentiation, as well as structural stability and functional maturation of the 3D heart organoid. By using the culture medium provided by the application, the 3D heart organoid can be prepared in a 3D dynamic environment, a 2D culture step is skipped, operation complexity is reduced, bionics is improved, and a 3D heart organoid culture period is shortened.

The application relates to the technical field of biological medicine, and discloses medical uses of HSPD1 acetylation modification in prevention or treatment of myocardial infarction. The application first finds that the acetylation level of an HSPD1 protein K352 site is specifically up-regulated in the pathological process of myocardial infarction, and that the heart function after myocardial infarction can be significantly improved by up-regulating the acetylation level of the site, and myocardial fibrosis and myocardial cell hypertrophy can be inhibited; the acetylation level of the site is down-regulated, and myocardial ischemic injury is aggravated, and the heart function is deteriorated. The application confirms that the HSPD1 K352 site acetylation can be used as a new target point for prevention, treatment and auxiliary diagnosis of myocardial infarction, and provides a theoretical basis and experimental basis for research and development of myocardial infarction targeted drugs and gene therapy products.

The present invention discloses a traditional Chinese medicine preparation for preventing and / or treating myocardial infarction, its preparation method and application, belonging to the technical field of pharmaceuticals. The traditional Chinese medicine is obtained by extracting Areca catechu with 20% - 95% ethanol. The present invention first reveals that the Areca catechu extract has an anti-myocardial infarction effect. The experimental results show that the crude extract of Areca catechu can significantly inhibit H2O2-induced cardiomyocyte death, improve the left ventricular ejection fraction of myocardial infarction mice, and reduce the myocardial infarction area, and the effect is equivalent to that of the positive drug Suxiao Jiuxin Pills, while arecoline has no cardiomyocyte protection effect. The present invention is of natural origin, simple to prepare, and low in cost, and can be used as a new supplement or alternative for clinical prevention and treatment of myocardial infarction, and has important clinical value and application prospects.

The application discloses application of recombinant human USP13 protein in preparation of a drug for treating diabetic cardiomyopathy, and belongs to the technical field of biological medicines.The application first proves that the expression of USP13 in myocardial tissue and serum is significantly reduced under the condition of diabetic cardiomyopathy (DCM); the recombinant human USP13 protein can obviously reduce the level of myocardial cell active oxygen, reduce the expression of NLRP3 inflammasome and active Caspase3 protein in a DCM in-vitro model induced by high sugar / palmitic acid; in a DCM mouse model injected with the recombinant human USP13 protein through a tail vein, myocardial cell apoptosis is inhibited, and the expression of NLRP3 inflammasome and the synthesis of TNF-alpha in the heart of the animal are reduced.USP13 is a human protein, has no obvious toxic side effects, is high in safety, is small in immunological rejection in theory, provides a new effective drug for the clinical treatment of DCM, and has important clinical application value and industrialization prospect.

The invention relates to the technical field of biomedicine and cardiovascular disease treatment, and discloses application of an Aralar myocardial overexpression virus in preparation of a medicine for treating heart failure. The related product is a gene therapy preparation containing an effective amount of AAV9-cTnT-Aralar, and can be matched with pharmaceutically acceptable carriers, diluents and other auxiliary materials, and the preparation is an injection type. The preparation method comprises the following steps: firstly, constructing a cardiac troponin T-carrying promoter and an AAV9 carrier of an Aralar coding nucleic acid to form a recombinant adeno-associated virus, and then matching the virus with proper auxiliary materials to prepare the preparation. The product can be used for treating heart failure accompanied with mitochondrial dysfunction, can realize heart targeted delivery and myocardial cell specific overexpression of Aralr, relieves the heart failure course by improving the myocardial cell mitochondrial function and dynamic balance, and is good in preparation stability, convenient in administration and adaptive to clinical application requirements.

The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes.

This invention discloses a myocardial protective composition of *Dioscorea opposita* polysaccharide, its preparation method, and its application, belonging to the field of natural products and functional foods. The active ingredient of the composition is one or a combination of *Dioscorea opposita* polysaccharide and *Dioscorea cirrhosa* polysaccharide. This polysaccharide is a neutral heteropolysaccharide mainly composed of glucose, with glucose accounting for more than 96% of the total monosaccharide mass. The two polysaccharides have highly similar molecular weight distributions and core structural characteristics. This invention demonstrates that the yam polysaccharide can dose-dependently improve the viability of cardiomyocytes after oxygen-glucose deprivation / reoxygenation injury, and reduce the levels of myocardial injury markers CK-MB and cTnT, and the oxidative stress marker 8-OHdG. Its core mechanism of action is the regulation of the MyD88-mediated MAPK / NF-κB signaling pathway, inhibiting the stress and inflammatory cascade response of cardiomyocytes. The yam polysaccharide composition of this invention has widely available raw materials, a simple preparation process, and high safety. It can be widely used in the preparation of pharmaceuticals, health foods, functional foods, and other products for the prevention / improvement of myocardial ischemia-reperfusion injury, and has broad application prospects.

The application belongs to the technical field of biological nanomaterials, and particularly relates to a nano-enzyme material and a preparation method and application thereof. The application reacts dimethyl imidazole and metal salt in an aqueous solution to obtain a metal-dimethyl imidazole composite material solution, wherein the metal salt comprises copper salt and / or zinc salt; and reacts the metal-dimethyl imidazole composite material solution and tannic acid to obtain a nano-enzyme material. The nano-enzyme material provided by the application has excellent antioxidant enzyme-like catalytic activity and good biocompatibility, can effectively remove abnormally increased reactive oxygen species (ROS) in the process of myocardial infarction and myocardial ischemia-reperfusion injury, inhibit inflammatory response and myocardial cell apoptosis, improve the mitochondrial function state, thereby promoting the repair of damaged myocardial tissue and significantly improving the cardiac function, and provides a new technical solution for the treatment of myocardial infarction and related ischemic cardiovascular diseases.